Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study

OBJECTIVES: Examine the probability of new active substances (NASs) approved in Canada between 1 January 1997 and 31 March 2012 acquiring a serious postmarket safety warning. DESIGN: Cohort study. DATA SOURCES: Annual reports of the Therapeutic Products Directorate and the Biologic and Genetic Thera...

Descripción completa

Detalles Bibliográficos
Autor principal: Lexchin, Joel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Health Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931983/
https://www.ncbi.nlm.nih.gov/pubmed/24549164
http://dx.doi.org/10.1136/bmjopen-2013-004289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931983/
https://www.ncbi.nlm.nih.gov/pubmed/24549164
http://dx.doi.org/10.1136/bmjopen-2013-004289

Ejemplares similares